Researcher
Marc Peeters
- Research Expertise (University of Antwerp):My expertise is in the field of oncology or cancer research. It is mainly focused on clinical translational research. This domain is very broad and ranges from bio-research to clinical studies
- Keywords (University of Antwerp):ONCOLOGY, Medicine
- Disciplines (Ghent University):Endocrinology and metabolic diseases, Paediatrics and neonatology, Nursing
- Disciplines (University of Antwerp):Cancer therapy, Cancer biology, Cancer diagnosis, Cancer epidemiology, Cancer prevention
- Research techniques (University of Antwerp):Making protocols for studies. (Statistical) analysis of results
- Users of research expertise (University of Antwerp):Other researchers in the field. Students Pharma and Biotech companies
- See also: Marc Peeters (Ghent University)
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Responsible
From1 Oct 2009 → 31 Dec 2018 - Department of Internal medicine (Department)
Member
From1 Oct 2000 → 30 Sep 2018
Projects
1 - 10 of 67
- Dawn of a new era in drug discovery: the symphony of AI-guided small molecule design with 3D patient-derived tumor organoids.From1 Jan 2024 → TodayFunding: IOF - technology concept exploration
- Trapped ion mobility quadrupole time of flight mass spectrometer hyphenated to automated high throughput liquid chromatography.From30 Jun 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Neuroendocrine neoplasms from bench to bedside: unravelling personalised strategies through the integration of clinical data and patientderived organoids.From1 Mar 2023 → 29 Feb 2024Funding: Nonprofit institution or equivalents
- Detection and quantification of a panel of clinically relevant DNA biomarker sequences containing KRAS mutations in tissue and liquid biopsies via a novel photoelectrochemical technology.From1 Jan 2023 → TodayFunding: FWO Humanitarian research project Stand up against Cancer
- Multiplexed photoelectrochemical detection technology for molecular cancer biomarkers (MultiSens).From1 Jan 2023 → 31 Dec 2023Funding: IOF - technology validation in lab
- A new photoelectrochemical singlet oxygen-based detection platform for a panel of cancer biomarkers in tissue and liquid biopsies (SOCAN).From1 Jan 2023 → TodayFunding: BOF - iBOF, University - Project driven research
- Improving diagnostic accuracy and follow-up of neuroendocrine neoplasms through detection of (epi)genetic biomarkers in liquid biopsies using novel technological platforms.From1 Nov 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Investigation to reveal the immune reaction upon COVID vaccination in the Belgian cancer population: COVID protection and vaccine safety (REAL-V).From1 Oct 2022 → TodayFunding: Nonprofit institution or equivalents
- Towards informed decisions in colorectal cancer screening (ORIENT).From15 Aug 2022 → TodayFunding: Nonprofit institution or equivalents
- Center for Proteomics (CfP).From1 Jan 2022 → TodayFunding: BOF - research organisations
Publications
41 - 50 of 385
- Longitudinal copy-number alteration analysis in plasma cell-free DNA of neuroendocrine neoplasms is a novel specific biomarker for diagnosis, prognosis, and follow-up(2022)
Authors: Gitta Boons, Timon Vandamme, Laura Mariën, Willem Lybaert, Geert Roeyen, Tim Rondou, Konstantinos Papadimitriou, Katrien Janssens, Bart op de Beeck, Marc Simoens, et al.
Pages: 338 - 349 - Development, testing, and implementation of the Belgian Patient Reported Experience Measure for Pancreatic Cancer Care (PREPARE) project(2022)
Authors: Katrien Moens, Marc Peeters, Marc Van den Bulcke, Mark Leys, Melissa Horlait
Pages: 1 - 8 - Excellent response to MEK inhibition in an AGK-BRAF gene fusion driven carcinoma(2022)
Authors: Carl Van Paesschen, Karen Zwaenepoel, Suzan Lambin, Patrick Pauwels, Marika Rasschaert, E.V.A. Segelov, Marc Peeters, Hans Prenen
Pages: 373 - 379 - Prognostic implications of cellular senescence in resected non-small cell lung cancer(2022)
Authors: Christophe Deben, Ines De Pauw, Christophe Hermans, Hilde Lambrechts, Jasper Verswyvel, Vasiliki Siozopoulou, Patrick Pauwels, Marco Demaria, Mick van de Wiel, Jeroen Hendriks, et al.
Pages: 1526 - 1539 - Point scintillator dosimetry in ultra-high dose rate electron "FLASH" radiation therapy(2022)
Authors: Verdi Vanreusel, Federica Galante, Giulia Mariani, Matteo Pacitti, Madalina Cociorb, Andrea Giammanco, Brigitte Reniers, Nathalie Reulens, Tunde Blessed Shonde, Hugo Vallet, et al.
Pages: 127 - 137 - Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma(2022)
Authors: Delphine Vervloet, Dieter Berwouts, Roel Beckers, Hans Prenen, Marc Peeters, Félix Gremonprez, Lieselot Croes, Christof Vulsteke
Pages: 1 - 7 - Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the “interval cancer” perspective(2022)
Authors: Thuy Ngan Tran, Marc Peeters, Sarah Hoeck, Guido Van Hal, Sharon Janssens, Harlinde De Schutter
Pages: 1091 - 1099 - Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer(2022)
Authors: Geert Roeyen, F. Berrevoet, I Borbath, K. Geboes, Marc Peeters, B. Topal, E. Van Cutsem, J-L Van Laethem
Pages: 1 - 9 - PRECISION(2022)
Authors: J. Thouvenin, C. Van Marcke, L. Decoster, G. Raicevic, K. Punie, M. Vandenbulcke, R. Salgado, E. Van Valckenborgh, B. Maes, S. Joris, et al.
Pages: 1 - 8 - ESMO Congress 2021(2022)
Authors: T. Koessler, M. Alsina, D. Arnold, I Ben-Aharon, M. Collienne, M.P. Lutz, C. Neuzillet, R. Obermannova, Marc Peeters, F. Sclafani, et al.
Pages: 1 - 8
Patents
1 - 6 of 6
- Combination immunotherapy of il-15 and cd40 agonist in cancer treatment (Inventor)
- Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment (Inventor)
- Methylation detection assay (Inventor)
- Methylation status of gasdermin E gene as cancer biomarker (Inventor)
- Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment (Inventor)
- Methylation status of gasdermin e gene as cancer biomarker (Inventor)